ClinicalTrials.gg
Active, not recruitingNCT05060822Updated Apr 21, 2026

Phase ll Study of HEC585 in Patients With IPF

A Phase 2 interventional study of HEC585 and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Sunshine Lake Pharma Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
19th of 60
270 · median 83
Started
2021
with 9 others
Phase 2
21 of 67
7 open now
Primary completion
2025-07
later than 1 of 28 live
Registered
18th of 67
by date
Lead sponsor
5 of 67
Sunshine Lake Pharma Co., Ltd.

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 19th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2021, is one of 21 in phase 2, reaches primary completion later than 1 of the 28 other live ones, and was the 18th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer to participate in this clinical study and sign the ICF before the study begins;
  • Aged 40-80 (including 40 and 80) ;
  • Female or male subjects with who agree and promise to take effective measures;
  • Diagnosed with IPF according to the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline for IPF Diagnosis (2018);
  • /FVC ≥ 0.7;
  • FVC ≥ 45% predicted;
  • DLCO corrected for (Hb) ≥ 30% predicted of normal;
  • In the opinion of the Investigator, subjects are willing and able to comply with the protocol requirements and attend the visit.

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the Investigator, subjects underwent significant deterioration in IPF within one month before randomization;
  • Interstitial lung disease caused by other known causes;
  • Any bacterial, viral, parasitic or fungal infection that needs to be treated at screening;
  • Expected to receive lung transplantation during the study;
  • Expected survival is less than 6 months;
  • History of tumors within 5 years before screening (except for localized cancers such as basal cell carcinoma);
  • Moderate to severe hepatic insufficiency ( grade B or C, see Appendix 4);
  • History of unstable or worsening heart disease within 6 months before screening;
  • Cannot perform 6MWT or PFT;
  • Allergic to any component of HEC585 Tablets or pirfenidone tablets;
  • Participated in other clinical study and received the last dose within 3 months before screening;
  • Pregnant or breastfeeding;
  • History of smoking within 3 months before screening or are unwilling to quit smoking during the study;
  • Subjects often drink alcohol within 6 months before the screening (drink more than 21 units of alcohol a week), or refuse to reduce alcohol intake during the study;
  • History of drug abuse within 6 months before the screening;
  • Family or personal history of syndrome;
  • Any condition that, in the opinion of the investigator, would compromise the safety or compliance of the subject, or prevent the subject from completing the study.
  • TBil > 1.5 × or or ALT > 2 × ULN;
  • \< 50 mL/min;
  • (HIV) antibody is positive;
  • Uncontrolled virus infection or virus infection;
  • QTcF > 480 ms.
  • Subjects have received any of the following treatments within 28 days before randomization:

    1. Any cytotoxic drug or
    2. Therapeutic drugs for IPF, including but not limited to pirfenidone, nintedanib, prednisone at > 15 mg/d or other of the equivalent dose, N-acetylcysteine at > 600 mg/d.
    3. Moderate and strong inhibitor or strong inducer of CYP1A2.
    4. Strong inducers or strong inhibitors.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    HEC585 dose A

    Drug: HEC585 dose A once daily, up to 24 weeks-120 weeks

    Drug: HEC585

  • Experimental
    HEC585 dose B

    Drug: HEC585 dose B once daily, up to 24 weeks-120 weeks

    Drug: HEC585

  • Experimental
    HEC585 dose C

    Drug: HEC585 dose C once daily, up to 24 weeks-120 weeks

    Drug: HEC585

  • Active comparator
    pirfenidone

    Drug: pirfenidone three times a day (target dose), up to 24 weeks

    Drug: Pirfenidone

  • Placebo comparator
    placebo

    Drug: placebo once daily, up to 24 weeks-120 weeks

    Drug: Placebo

Interventions

  • DrugHEC585

    HEC585 Tablets,once daily

  • Pirfenidone,three times a day

  • DrugPlacebo

    Placebo,once daily

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 24 in %FVC compared with placebo

    change in %FVC, measured using Spirometer, from baseline to week 24

    Time frame: 24 Weeks

Secondary outcomes

  1. Change from Baseline to Week 24 in %FVC compared with Pirfenidone

    change in %FVC, measured using Spirometer, from baseline to week 24

    Time frame: 24 Weeks

  2. Change from Baseline to Week 12 in %FVC compared with placebo/ Pirfenidone

    change in %FVC, measured using Spirometer, from baseline to week 12

    Time frame: 12 Weeks

  3. Proportion of subjects with an absolute decline from baseline in FVC (% predicted) of > 10%

    The proportion of subjects whose %FVC decline from baseline by more than 10% in each treatment group at W24

    Time frame: 24 Weeks

  4. Time to first acute IPF exacerbation

    Time frame: 24 Weeks

  5. All-cause mortality

    Time frame: 24 Weeks

  6. IPF related mortality

    Time frame: 24 Weeks

  7. Changes of 6MWT results

    Time frame: 12 Weeks, 24 Weeks

  8. Changes of SGRQ scores

    Time frame: 12 Weeks, 24 Weeks

  9. Changes of DLco (Hb correction)

    Time frame: 12 Weeks, 24 Weeks

  10. Changes of resting SpO2

    Time frame: 12 Weeks, 24 Weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2025, 48 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 48 months is above that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2021
First posted
Sep 29, 2021
StartActual
Jun 30, 2021
Primary completionActual
Jul 16, 2025
CompletionEst.
Dec 11, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05060822
Responsible party
Sponsor
First posted
Sep 29, 2021
Start date
Jun 30, 2021
Primary completion
Jul 16, 2025
Completion
Dec 11, 2026 (estimated)
Last update
Apr 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yinfenidone

Start the discussion